Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafamidis effect on Rosuvastatin PK in Healthy Participants
NCT04253353Phase 1Completed
- Sponsor
- Pfizer
- Start
- Feb 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tafamidis in transthyretin amyloidosis (ATTR), sponsored by Pfizer. Primary endpoints: Area under the plasma concentration-time profile from time 0 extrapolated to infinity for rosuvastatin and Apparent renal clearance for rosuvastatin. Started Feb 2020; status: completed.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT04253353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04253353.